Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK7 | P50613 | 15/20 | 0.49 |
| ▸ | CCNH | P51946 | 15/20 | 0.49 |
| ▸ | MNAT1 | P51948 | 14/20 | 0.49 |
| ▸ | CCNK | O75909 | 12/20 | 0.49 |
| ▸ | CDK12 | Q9NYV4 | 12/20 | 0.49 |
| ▸ | CCNT1 | O60563 | 7/20 | 0.44 |
| ▸ | CDK9 | P50750 | 7/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 6/20 | 0.44 |
| ▸ | CDK2 | P24941 | 6/20 | 0.44 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.39 |
| ▸ | CCND1 | P24385 | 1/20 | 0.39 |
| ▸ | CCND3 | P30281 | 1/20 | 0.39 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21184557 | 0.96 | CDK7 (0.51) | CDK7CCNHMNAT1CCNKCDK12 | |
| SCHEMBL24176230 | 0.92 | CDK7 (0.44) | CDK7CCNHMNAT1CCNKCDK12 | |
| SCHEMBL21184597 | 0.92 | CDK7 (0.45) | CDK7CCNHMNAT1CCNKCDK12 | |
| SCHEMBL24176320 | 0.92 | CDK7 (0.45) | CDK7CCNHMNAT1CCNKCDK12 | |
| SCHEMBL24176261 | 0.91 | CDK7 (0.44) | CDK7CCNHMNAT1CCNKCDK12 | |
| SCHEMBL21184593 | 0.91 | CDK7 (0.53) | CDK7CCNHMNAT1CCNKCDK12 | |
| SCHEMBL21184556 | 0.90 | CDK7 (0.47) | CDK7CCNHMNAT1CCNKCDK12 | |
| SCHEMBL21184310 | 0.89 | CDK7 (0.43) | CDK7CCNHMNAT1CCNKCDK12 | |
| SCHEMBL21184406 | 0.89 | CDK7 (0.53) | CDK7CCNHMNAT1CCNKCDK12 | |
| SCHEMBL24176326 | 0.89 | CDK7 (0.42) | CDK7CCNHMNAT1CCNKCDK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220000890-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | MEDIC LIFE SCIENCES, INC. | 2022-01-06 | — | — | US | disclosed |
| WO-2019143730-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2019-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220000890-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CCNK | CDK7 1/4885CCNH 24/4885MNAT1 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.